Madrigal Pharmaceuticals, Inc. Common Stock
MDGL
$452.86
-5.90%
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. The company is a first-mover and potential market leader in the MASH space with its lead asset, Rezdiffra (resmetirom), an oral, once-daily thyroid hormone receptor beta agonist that received FDA approval in March 2024. The current investor narrative is dominated by the commercial launch trajectory of Rezdiffra, with intense focus on quarterly revenue ramp, market penetration against competing therapies, and the company's ability to transition from a cash-burning R&D entity to a profitable commercial organization, as evidenced by its first full year of product revenue in 2025.…
MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
$452.86
Related headlines
MDGL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Madrigal Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $588.72 and implied upside of +30.0% versus the current price.
Average Target
$588.72
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$362 - $589
Analyst target range
Insufficient analyst coverage data is available in the provided dataset to determine a consensus price target, Buy/Hold/Sell distribution, or a specific target range. The data indicates only 5 analysts providing estimates, and no average target price is listed. Limited coverage is typical for a mid-cap biotechnology company that has recently transitioned to commercial stage, but it can lead to higher volatility and less efficient price discovery as the investment story is still being established among the broader institutional community.
The institutional ratings data shows a pattern of reiterated bullish calls from several firms (e.g., Overweight from Piper Sandler, Buy from B. Riley, HC Wainwright, and Truist) following the Q3 2025 earnings report in November, with no downgrades noted in the sample. The most recent action was a reaffirmed 'Neutral' from B of A Securities in February 2026. This pattern suggests existing coverage remains generally positive, focused on the commercial execution of Rezdiffra, but the lack of a broad consensus target underscores the uncertainty and wide range of potential outcomes for the launch.
Bulls vs Bears: MDGL Investment Factors
The bull case for MDGL is compelling, anchored by explosive revenue growth from its first-in-class MASH drug and a clear path to profitability, as evidenced by rapidly improving margins. However, the bear case presents substantial risks, primarily the company's precarious cash position, extreme dependency on a single product, and a premium valuation that leaves no room for error. Currently, the bull side has stronger evidence due to the concrete, accelerating commercial success of Rezdiffra. The single most important tension in the investment debate is whether the company can achieve cash flow breakeven through continued sales growth before needing to raise dilutive capital, thereby validating its current premium multiple.
Bullish
- Explosive Revenue Growth: Rezdiffra's commercial launch has driven revenue from $0 in Q1 2024 to $321.1 million in Q4 2025, a 211% year-over-year growth rate for that quarter. Sequential quarterly revenue growth from $137.3M to $321.1M in 2025 validates strong market uptake and the significant unmet need in MASH.
- Rapid Path to Profitability: The net loss narrowed from -$114.2 million in Q3 2025 to -$58.6 million in Q4 2025, and the operating margin improved from -39.7% to -18.6% over the same period. This demonstrates powerful operating leverage as sales scale, moving the company closer to cash flow breakeven.
- First-Mover Advantage in MASH: Rezdiffra is the first FDA-approved oral therapy for MASH, providing a significant commercial head start in a multi-billion dollar market. The company's valuation premium (P/S of 13.6x) reflects this leadership position and the lack of near-term competition for an oral treatment.
- Strong Institutional Sentiment: Recent analyst actions show reiterated bullish calls (e.g., Overweight from Piper Sandler, Buy from B. Riley) following Q3 2025 earnings. This pattern suggests institutional confidence in the commercial execution story despite the stock's recent technical weakness.
Bearish
- Deeply Negative Free Cash Flow: Trailing twelve-month free cash flow is -$190.0 million, and the company ended Q4 2025 with only $203.8 million in cash. This necessitates a near-term capital raise to fund operations, risking shareholder dilution or increased debt burden.
- Extreme Valuation & Growth Dependency: The stock trades at a trailing P/S of 13.6x, a premium valuation that demands flawless execution and sustained high growth. Any deceleration in the revenue ramp from the current 211% YoY pace could trigger severe multiple compression.
- Single-Asset, Single-Market Risk: 100% of revenue is derived from Rezdiffra for MASH, creating immense concentration risk. Clinical setbacks, competitive launches, or payer reimbursement issues for this one drug would have catastrophic financial implications.
- Technical Downtrend & High Volatility: The stock is down -16.70% over six months and -4.11% over one month, underperforming the SPY by -10.42% recently. It trades at 71% of its 52-week range, showing significant retreat from highs and high volatility, as seen in the surge from $462 to $519 on March 26th.
MDGL Technical Analysis
The stock is in a pronounced downtrend over the past six months, with a price change of -16.70% over that period, contrasting sharply with its strong 1-year performance of +84.22%. Currently trading at $497.27, the price sits at approximately 71% of its 52-week range ($265.20 to $615.00), indicating it has retreated significantly from its highs but remains well above its lows, suggesting a phase of consolidation after a major rally. The short-term momentum is negative and diverging from the longer-term uptrend, with the stock down -4.11% over the past month and underperforming the SPY by -10.42% on a relative strength basis, signaling potential near-term weakness or profit-taking.
Recent price action shows significant volatility, with the stock surging from $461.93 to $518.76 on March 26th before retreating, highlighting the influence of news flow and high-beta trading. Key technical support is the 52-week low area around $265, while immediate resistance is the recent high near $615; a sustained break above $615 would signal a resumption of the primary uptrend, while a breakdown below $400 could indicate a deeper correction. The stock's beta of -1.045 is anomalous and suggests an inverse relationship to the broader market in the provided dataset, which, if accurate, implies unique, non-systematic risk drivers, though this figure should be verified against standard market data.
Beta
-1.04
-1.04x market volatility
Max Drawdown
-29.4%
Largest decline past year
52-Week Range
$269-$615
Price range past year
Annual Return
+66.1%
Cumulative gain past year
| Period | MDGL Return | S&P 500 |
|---|---|---|
| 1m | -11.8% | +5.4% |
| 3m | +4.2% | +10.9% |
| 6m | -22.7% | +11.0% |
| 1y | +66.1% | +28.1% |
| ytd | -23.7% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDGL Fundamental Analysis
Revenue trajectory has transformed dramatically with the launch of Rezdiffra, growing from $0 in Q1 2024 to $321.1 million in Q4 2025, representing a year-over-year growth rate of 211% for that quarter. The multi-quarter trend shows accelerating commercial sales, with revenue increasing sequentially from $137.3 million in Q1 2025 to $321.1 million in Q4 2025, indicating strong initial uptake and validating the significant market opportunity in MASH. This growth is singularly driven by the Rezdiffra product launch, as the company has no other commercialized segments.
The company remains unprofitable on a net income basis, reporting a loss of $58.6 million in Q4 2025, but gross margins are exceptionally high at 94.2%, typical for a pharmaceutical company with a novel drug. The net loss has narrowed significantly from -$114.2 million in Q3 2025 to -$58.6 million in Q4 2025, demonstrating improving operating leverage as revenue scales, moving the company closer to profitability. The operating margin improved to -18.6% in Q4 2025 from -39.7% in Q3 2025, highlighting rapid margin expansion.
Financial health is mixed, with a strong current ratio of 4.01 indicating ample short-term liquidity, and a manageable debt-to-equity ratio of 0.59. However, free cash flow remains deeply negative at -$190.0 million on a trailing twelve-month basis, and the company ended Q4 2025 with $203.8 million in cash, suggesting it will likely require additional capital to fund operations and growth before reaching cash flow breakeven. Return on equity is deeply negative at -47.8%, reflecting the significant accumulated losses during the drug development phase.
Quarterly Revenue
$321083000.0B
2025-12
Revenue YoY Growth
+2.10%
YoY Comparison
Gross Margin
+0.92%
Latest Quarter
Free Cash Flow
$-190020000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDGL Overvalued?
Given the company's negative net income of -$58.6 million, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 13.63x, while the forward-looking metric is implied by analyst revenue estimates averaging $4.97 billion, which would suggest a significantly lower forward PS ratio based on the current market cap, indicating the market is pricing in substantial revenue growth. The gap between trailing and implied forward multiples reflects high growth expectations embedded in the stock price.
Peer comparison is challenging without explicit industry average data in the provided valuation set, but a PS ratio of 13.6x for a biotech company in the early stages of a major launch is typically at a premium to more mature pharmaceutical firms but may be in line with high-growth commercial-stage biotechs. The valuation premium would need to be justified by Rezdiffra's peak sales potential, market leadership, and lack of near-term competition in the oral MASH therapy market.
Historically, the stock's own PS ratio has compressed dramatically from extreme levels (e.g., 408.4x in Q2 2024 when revenue was minimal) to the current 13.6x as revenue has materialized. The current PS of 13.6x is near the lower end of its observable historical range since launch, suggesting the market has already priced in a significant portion of the near-term commercial success, moving from a speculative, revenue-less valuation to one grounded in actual sales figures.
PE
-45.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -56x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-50.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute. The company is burning cash at a rate of -$190.0 million TTM and holds only $203.8 million in cash, implying a runway of less than four quarters at the Q4 burn rate. This almost guarantees a capital raise within 12 months, posing a high risk of shareholder dilution. Furthermore, the entire business is concentrated in one drug, Rezdiffra, which generated 100% of Q4 2025's $321.1 million revenue. Any disruption in its commercial trajectory would immediately crater financials. While margins are improving, the company remains deeply unprofitable with a -30.1% net margin, making it wholly dependent on continued hyper-growth.
Market & Competitive Risks center on valuation and competition. Trading at a trailing P/S of 13.6x, MDGL carries a significant growth premium. If quarterly revenue growth decelerates from the current 211% YoY pace, severe multiple compression is likely, as seen historically when its P/S collapsed from 408x pre-revenue to current levels. Although a first-mover, the MASH market is attractive and will inevitably attract new competitors, threatening Rezdiffra's market share and pricing power. The stock's anomalous beta of -1.045, if accurate, suggests it trades on idiosyncratic news rather than market trends, increasing volatility and making it harder to hedge with broad market exposure.
The Worst-Case Scenario involves a combination of a slower-than-expected revenue ramp, prompting analyst downgrades, coupled with the necessity of a highly dilutive equity offering amid weak market sentiment. This could trigger a downward spiral where the stock re-tests its 52-week low of $265.20. A realistic downside from the current price of $497.27 to this level represents a loss of approximately -47%. Additional triggers could include adverse clinical data for Rezdiffra, a successful competitive launch, or significant payer pushback on drug pricing, any of which could accelerate the decline toward this bear-case floor.